bit.bio
bit.bio is an award-winning human synthetic biology company whose mission is to code cells for novel cures. They have developed an end-to-end platform for the creation of any human cell type. With their cutting-edge and patent-protected opti-ox™ precision cell programing technology, bit.bio can deterministically program human induced pluripotent stem cells (iPSCs) into a chosen cell identity with unprecedented biological consistency at an industrial scale and approximately 10 times faster than conventional methods. Their platform has the potential to unlock a new generation of medicines.
Latest Content
Industry Insight
Simplifying Cell Visualization in Complex Model Systems
bit.bio’s GFP ioMicroglia enables real-time tracking of microglia in complex co-cultures and in vivo, streamlining neurodegeneration research and drug discovery.
Product News
bit.bio Launches ioTracker Cells Range at SLAS 2025
bit.bio, announces the launch of its ioTracker Cells range, starting with GFP ioMicroglia, a progressive tool designed to accelerate complex neurodegenerative disease research and drug discovery.
Webinar
Human iPSC-Based Models of Glial Cells for Studying Neurodegenerative Disease
On-Demand
The increasing implication of glial cells in neurodegenerative diseases makes them an appealing addition to iPSC-based model systems for investigating disease mechanisms.
Industry Insight
Exploring Human iPSC-Derived Astrocytes for Advancing CNS Research
In this interview, Dr. Mitzy Rios de Anda sheds light on the potential of human iPSC-derived astrocytes, discussing how these cells are reshaping our understanding of the brain, neurological diseases and therapeutic development.
Video
Leveraging Human iPSC-Derived Astrocytes for Neurological Research and Therapy
In this episode we speak with bit.bio about astrocytes and how bit.bio's innovative technology is transforming research in this area.
Webinar
Powering a New Generation of Physiologically-Relevant CRISPR Screens
On-Demand
CRISPR-Cas9 gene editing is an essential functional genomics tool, facilitating the cataloging of genomic variations linked to human diseases for the discovery and validation of novel drug targets.
Product
Advertisement
ioAstrocytes - Human iPSC-Derived Astrocytes
ioAstrocytes offer a solution to researchers who are searching for easy-to-use, highly characterised human cells that are designed for co-culture and effectively recapitulate astrocyte functions within CNS models in vitro
App Note / Case Study
Studying the Link Between Cell Migration and Neurodegenerative Disease With iPSC-derived Microglia
In this application note, researchers from Medicines Discovery Catapult (MDC) evaluated the suitability of iPSC-derived microglia as a model for studying the mechanics of microglia activation, shedding light on their role in neurodegeneration and the potential for therapeutic targets.
App Note / Case Study
Improving Physiological Relevance in Neurological Disease Drug Development
This case study explores the use of human iPSC-derived microglial cells as a more reliable model for neurobiological drug development.
Poster
Improving Physiological Relevance in Functional Genomics Screens
This poster describes the use of CRISPR-ready iPSCs, which are engineered to constitutively express Cas9, enabling the rapid generation of high-efficiency gene knockouts and CRISPR screens in a functional, physiologically relevant cell background.
Advertisement
